Safety of corneal collagen cross-linking with UV-A and riboflavin in progressive keratoconus.
OBJECTIVE
To assess the possible damage to ocular tissues during treatment of keratoconus with UV-A-riboflavin corneal collagen cross-linking (CXL).


METHODS
Single center, prospective, interventional study.


METHODS
Fourteen eyes of 14 patients aged 28.2 ± 5.9 (mean ± SD) years with progressive keratoconus were treated with UV-A-riboflavin CXL. Corneal endothelium was assessed with the endothelial specular microscope. Central retina was assessed with biomicroscopy fundus examination and with optical coherence tomography using macular thickness protocol. Patients were assessed preoperatively, at week 1, month 1, 3, 6, 9, and 12 after treatment.


RESULTS
Comparative preoperative and postoperative results showed stable endothelial cell density (2730 cells/mm, 2793 cells/mm, and 2640 cells/mm, preoperatively, at month 6, and at month 12, respectively) and stable foveal thickness (203, 202, and 205 μm, preoperatively, at month 6, and at month 12, respectively). No morphological abnormalities were noted.


CONCLUSIONS
UV-A-riboflavin CXL seems to be a safe procedure that does not cause damage to the corneal endothelium and central retina.
Goldich
Yakov
Y
Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel. doctor.goldich@gmail.com
Marcovich
Arie L
AL
Barkana
Yaniv
Y
Avni
Isaac
I
Zadok
David
D
D000328:Adult; D002452:Cell Count; D003094:Collagen / Q000378:metabolism / Q000528:radiation effects*; D003319:Corneal Stroma / Q000187:drug effects / Q000378:metabolism; D019781:Corneal Topography; D003432:Cross-Linking Reagents / Q000009:adverse effects / Q000627:therapeutic use*; D004728:Endothelium, Corneal / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D005260:Female; D006801:Humans; D007640:Keratoconus / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D012256:Riboflavin / Q000009:adverse effects / Q000627:therapeutic use*; D014466:Ultraviolet Rays
D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin